BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Special Report

All Special Reports
GU Cancer US KOL Interview

Retail Price: $599.00

*BioMedTracker Subscriber Price: $399.00 - click here to log in
August 11, 2017
We interviewed a US-based KOL specializing in genitourinary (GU) cancers with a focus on immunotherapies for bladder and prostate cancers. Major topics included incorporation of immunotherapies for GU cancers, PD-L1 biomarker testing and combination therapies. The drugs discussed included Bavencio (avelumab, MKGAY), Cyramza (ramucirumab, LLY), Imfinzi (durvalumab, AZN), Keytruda (pembrolizumab, MRK), Opdivo (nivolumab, BMY), Tecentriq (atezolizumab, RHHBF) and Yervoy (ipilimumab, BMY).

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: Bladder Cancer
Prostate Cancer